1. Home
  2. GERN vs CBL Comparison

GERN vs CBL Comparison

Compare GERN & CBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • CBL
  • Stock Information
  • Founded
  • GERN 1990
  • CBL 1978
  • Country
  • GERN United States
  • CBL United States
  • Employees
  • GERN N/A
  • CBL N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • CBL Real Estate Investment Trusts
  • Sector
  • GERN Health Care
  • CBL Real Estate
  • Exchange
  • GERN Nasdaq
  • CBL Nasdaq
  • Market Cap
  • GERN 700.6M
  • CBL 777.7M
  • IPO Year
  • GERN 1996
  • CBL 1993
  • Fundamental
  • Price
  • GERN $1.46
  • CBL $31.70
  • Analyst Decision
  • GERN Buy
  • CBL
  • Analyst Count
  • GERN 8
  • CBL 0
  • Target Price
  • GERN $3.71
  • CBL N/A
  • AVG Volume (30 Days)
  • GERN 12.0M
  • CBL 137.2K
  • Earning Date
  • GERN 08-06-2025
  • CBL 08-06-2025
  • Dividend Yield
  • GERN N/A
  • CBL 5.69%
  • EPS Growth
  • GERN N/A
  • CBL 128.05
  • EPS
  • GERN N/A
  • CBL 2.10
  • Revenue
  • GERN $164,447,000.00
  • CBL $539,452,000.00
  • Revenue This Year
  • GERN $159.14
  • CBL N/A
  • Revenue Next Year
  • GERN $52.76
  • CBL N/A
  • P/E Ratio
  • GERN N/A
  • CBL $14.40
  • Revenue Growth
  • GERN 11877.20
  • CBL 2.20
  • 52 Week Low
  • GERN $1.09
  • CBL $21.10
  • 52 Week High
  • GERN $4.83
  • CBL $33.54
  • Technical
  • Relative Strength Index (RSI)
  • GERN 59.63
  • CBL 76.74
  • Support Level
  • GERN $1.26
  • CBL $30.13
  • Resistance Level
  • GERN $1.55
  • CBL $30.74
  • Average True Range (ATR)
  • GERN 0.09
  • CBL 0.64
  • MACD
  • GERN 0.02
  • CBL 0.18
  • Stochastic Oscillator
  • GERN 75.00
  • CBL 96.68

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

Share on Social Networks: